Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas No Evidence for prognostic significance

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3807-3812

  Hofmockel, Georg ^a   Wittmann, Andrea ^a   Dammrich, Jobst ^a   Bassukas, Ioannis D ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

bcl 2; Expression; P53; Prognosis; Renal cell carcinoma

Indexed keywords

GENE PRODUCT; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, P53; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030513772     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Chang F, Syrjanen S and Syrjanen K: Implications of e p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995.
2. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:1047-1054, 1991.
3. Wang Y, Szekely L, Okan I, Klein G, Wiman G and iman KL: Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427-3431, 1993.
4. Joensuu H, Pylkkanen L and Toikkanen S: bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198, 1994.
5. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991.
6. Starzynska T, Bromley M, Gosh A and Stern PL: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558-562, 1992.
7. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH and Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992.
8. Visakorpi, T, Kallioniemi OP, Heikkinen A, Koivula T and Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992.
9. Imai Y, Strohmeyer TO, Fleischhakcer M, Slamon DJ and Koeffler HP: p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 7:766-770, 1994.
10. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Rafe R, Tan HK and Jonas U: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71:201-205, 1995.
11. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546, 1992.
12. Brada M: Bcl-2 gene: current relevance to clinical oncology. Eur J Cancer 28:270-272, 1992.
13. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and box gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
14. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994.
15. Reiter RE, Anglard P, Liu S, Gnarra JR and Linehan WM: Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 53: 3092-309793.
16. Uhlman DL, Nguyen PL, Manivel JC, Aepli D, Resnick JM, Fraley EE and Zhang G: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86: 1470-1475, 1994.
17. Kuczyk MA, Serth J, Bokemeyer C, Arndt H, Jonassen J, Panitz F, Hofner K and Jonas U: [Frequency of p53-gene alterations in human renal cell cancer and correlation with clinical stage]. Akt Urol 26:47-50, 1995.
18. Bot FJ, Godschalk JC, Krishnadath KK, van-derKwast TH and Bosman FT: Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinicopathological parameters. Int J Cancer 57:634-637, 1994.
19. Kamel D, Turpeenniemi-Hujanen T, Vahakangas K, Paakko P and Soini Y: Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Histopathology 25:339-347, 1994.
20. Hofmockel G, Tsatalpas P, Müller H, Dammrich J, Poot M, Maurer-Schultze B, Muller-Hermelink HK, Frohmüller, H, Bassukas ID: Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 76:296-306, 1995.
21. Chin KV, Ueda K, Pastan I and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462, 1992.
22. Miyashita T and Reed JC: bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993.